<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431612</url>
  </required_header>
  <id_info>
    <org_study_id>Esmolol study</org_study_id>
    <nct_id>NCT01431612</nct_id>
  </id_info>
  <brief_title>Effects of Adrenergic Drugs on the Fluid Balance During Surgery</brief_title>
  <official_title>The Effects of ß1-receptor Blockade and α1-adrenergic Agonist on the Kinetics of Lactated Ringer's Solution During Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sodertalje Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sodertalje Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim this study was to examine to what degree the slow turnover of lactated Ringer's
      solution during anesthesia and surgery can be prevented by infusing esmolol (a ß1-receptor
      blocker) or phenylephrine in patients undergoing laparoscopic gynecological surgery performed
      under intravenous anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION The renal clearance of infused crystalloid fluid is very low during anaesthesia
      and surgery, but experiments in conscious sheep indicate that the renal fluid clearance might
      approach a normal rate when the adrenergic balance is modified.

      METHODS Sixty females (mean age, 32 years) undergoing laparoscopic gynecological surgery were
      randomized to control group and received only the conventional anesthetic drugs and 20 ml/kg
      of lactated Ringer's over 30 min. The others were also given an infusion of 50 µg/kg/min of
      esmolol (beta1-receptor blocker) or 0.01 µg/kg/min of phenylephrine (alpha1-adrenergic
      agonist) over 3 hours. The distribution and elimination of infused fluid was studied by
      volume kinetic analysis based on urinary excretion and blood Hgb level.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary excretion</measure>
    <time_frame>3 hours</time_frame>
    <description>Urine was collected via an indwelling catheter during 3 hours of surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume kinetics of lactated Ringer´s solution</measure>
    <time_frame>3 hours</time_frame>
    <description>Volume kinetics was analyzed based on serial analysis of the blood Hgb concentration and the collection of urine. Distribution between a central body and a peripheral body fluid space was then calculated over time.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Ovarian Cyst</condition>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 µg/kg/min of the ß-1-receptor-blocker esmolol (Qilu Pharmaceutical Co, Shandong, China) wss infused intravenously over 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous infusion of 0.01 µg/kg/min of phenylephrine (alpha1-adrenergic agonist) over 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactated Ringer´s solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol administration</intervention_name>
    <description>50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours</description>
    <arm_group_label>Esmolol</arm_group_label>
    <other_name>Drug by Qilu Pharmaceutical Co, Shandong, China</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine infusion</intervention_name>
    <description>0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine</description>
    <arm_group_label>Phenylephrine</arm_group_label>
    <other_name>Drug by Hefeng Pharmaceutical Co, Shanghai, China.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactated Ringer´s solution</intervention_name>
    <description>Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug</description>
    <arm_group_label>Lactated Ringer´s solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA group I

          -  Scheduled for laparoscopic removal of ovarian cyst or laparoscopic hysterectomy

        Exclusion Criteria:

          -  ASA group &gt; I

          -  Daily medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Hahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Södertälje Hospital, Södertälje, Sweden; Section for Anesthesia, Linköping University, Linköping, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology, First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Vane LA, Prough DS, Kinsky MA, Williams CA, Grady JJ, Kramer GC. Effects of different catecholamines on the dynamics of volume expansion of crystalloid infusion. Anesthesiology. 2004 Nov;101(5):1136-44.</citation>
    <PMID>15505449</PMID>
  </reference>
  <reference>
    <citation>Olsson J, Svensén CH, Hahn RG. The volume kinetics of acetated Ringer's solution during laparoscopic cholecystectomy. Anesth Analg. 2004 Dec;99(6):1854-60, table of contents.</citation>
    <PMID>15562086</PMID>
  </reference>
  <reference>
    <citation>Ewaldsson CA, Vane LA, Kramer GC, Hahn RG. Adrenergic drugs alter both the fluid kinetics and the hemodynamic responses to volume expansion in sheep. J Surg Res. 2006 Mar;131(1):7-14. Epub 2005 Dec 2.</citation>
    <PMID>16325856</PMID>
  </reference>
  <reference>
    <citation>Hahn RG. Volume kinetics for infusion fluids. Anesthesiology. 2010 Aug;113(2):470-81. doi: 10.1097/ALN.0b013e3181dcd88f.</citation>
    <PMID>20613481</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2011</study_first_posted>
  <last_update_submitted>September 7, 2011</last_update_submitted>
  <last_update_submitted_qc>September 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sodertalje Hospital</investigator_affiliation>
    <investigator_full_name>Robert Hahn</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics, kidney;</keyword>
  <keyword>Receptors, adrenergic;</keyword>
  <keyword>Fluids, i.v.;</keyword>
  <keyword>Sympathetic nervous system, esmolol;</keyword>
  <keyword>Sympathetic nervous system, phenylephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Esmolol</mesh_term>
    <mesh_term>Adrenergic Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

